Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Informed consent for neuroleptic therapy.

J Deveaugh-Geiss

    The American Journal of Psychiatry
    |July 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Informed consent is crucial for patients starting neuroleptic drugs due to tardive dyskinesia risks. Obtaining specific, written consent within six weeks can resolve many ethical issues.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.

    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2001
    Same author

    The effect of bupropion on nicotine craving and withdrawal.

    Psychopharmacology·2000
    Same author

    NSAIDs and cognition in Alzheimer's disease.

    Neurology·1996
    Same author

    Cognitive performance on the Alzheimer's Disease Assessment Scale: effect of education.

    Neurology·1995
    Same author

    Psychosis in Parkinson's disease: diagnosis and treatment.

    Progress in neuro-psychopharmacology & biological psychiatry·1995
    Same author

    Pharmacologic therapy of obsessive compulsive disorder.

    Advances in pharmacology (San Diego, Calif.)·1994

    Area of Science:

    • Neuroscience
    • Medical Ethics
    • Psychiatry

    Background:

    • Neuroleptic drugs are frequently prescribed for various conditions.
    • Tardive dyskinesia is a potential side effect of neuroleptic treatment, varying in frequency and severity.
    • Informed consent is a cornerstone of ethical medical practice.

    Purpose of the Study:

    • To highlight the necessity of informed consent for patients undergoing neuroleptic drug therapy.
    • To review the fundamental conditions for obtaining valid informed consent.
    • To discuss ethical challenges associated with the informed consent process in this context.

    Main Methods:

    • Review of existing literature and ethical guidelines regarding informed consent.
    • Analysis of the specific risks associated with neuroleptic drugs, particularly tardive dyskinesia.
    Keywords:
    Tardive Dyskinesia

    Related Experiment Videos

  • Discussion of practical and ethical considerations in obtaining patient consent.

    • Main Results:

    • The frequency and severity of tardive dyskinesia necessitate informed consent.
    • Three basic conditions for informed consent are essential.
    • Specific, written informed consent obtained within six weeks of therapy initiation can mitigate most ethical problems.

    Conclusions:

    • Informed consent is mandatory for patients receiving neuroleptic drugs.
    • Addressing ethical concerns requires a structured approach to obtaining consent.
    • While generally resolvable, challenges in the possibility of obtaining consent in some cases remain.